当前位置: 首页 >> 检索结果
1. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
作者: Elissa Malkin.;Marija Zaric.;Mark Kieh.;Lindsey R Baden.;David Fitz-Patrick.;Arianna Marini.;Heejin Yun.;Peter Hayes.;Rachel Bromell.;Morolayo Ayorinde.;Natalia Fernandez.;Ruhani Varma.;Faith Sigei.;Matthew Ward.;Hema Pindolia.;Shayna Sewell.;Fahimah Amini.;Julie Blie.;Barthalomew Wilson.;Patrick Faley.;John McCullough.;Franklin Tokpah.;Cecelia Wisseh.;Elvis Towalid.;Swapnil Hadawale.;Eddy Sayeed.;Devin Hunt.;Nahid Keshavarzi.;Burc Barin.;Irina Maljkovic Berry.;Christopher L Parks.;Shobhna Gopal Truter.;Kathleen Walker.;Johan Vekemans.;Jennifer Lehrman.;Michelle Engelbrecht.;Mariette Malherbe.;Dagna Laufer.;Vincent Philiponis.;Elizabeth Higgs.;Gaudensia Mutua.;Patricia E Fast.;Swati B Gupta.; .
来源: N Engl J Med. 2025年393卷18期1807-1818页
No vaccine is currently available for Lassa fever, a viral hemorrhagic disease that is estimated to cause thousands of deaths each year in western Africa. A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSVΔG-LASV-GPC, has been developed, but data on its safety and immunogenicity are limited.
2. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
作者: Robert Bissonnette.;Jennifer Soung.;Adelaide A Hebert.;Andrew E Pink.;Andreas Pinter.;Angela Y Moore.;Yuling Shi.;Wen-Hui Wang.;Darryl P Toth.;Megan Miller-Kassamali.;Joseph Cafone.;Jingzhi Jiang.;Shu Li.;Cynthia M C DeKlotz.;Fabio Nunes.;Mark G Lebwohl.
来源: N Engl J Med. 2025年393卷18期1784-1795页
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis.
3. Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.
作者: Ian H Kunkler.;Nicola S Russell.;Niall Anderson.;Richard Sainsbury.;J Michael Dixon.;David Cameron.;Juliette Loncaster.;Matthew Hatton.;Helen Westenberg.;Jackie Clarke.;Heather McCarty.;Rhun Evans.;Konstantinos Geropantas.;Virginia Wolstenholme.;Abdulla Alhasso.;Pamela Woodings.;Lisa Barraclough.;Neil Bayman.;Richard Welch.;Fidelis Muturi.;Tracy McEleney.;Jacqueline Burns.;Kathleen Riddle.;Eve Macdonald.;Joanna Dunlop.;Nicole Sergenson.;Geertjan van Tienhoven.;Karen J Taylor.;John M S Bartlett.;Tammy Piper.;Galina Velikova.;Edwin Aird.;Boon Chua.;Coen Hurkmans.;Karen Venables.;Linda J Williams.;Jeremy S Thomas.;Andrew M Hanby.;Marjory Maclennan.;Susan Cleator.;Eldo T Verghese.;Yexiong Li.;Shulian Wang.;Peter Canney.; .; .
来源: N Engl J Med. 2025年393卷18期1771-1783页
The role of postmastectomy chest-wall irradiation in patients with breast cancer classified as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node negative) with additional risk factors is uncertain.
4. Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.
作者: Naina McCann.;Margarete Paganotti Vicentine.;Narges Ebrahimi.;Melanie Greenland.;Brian Angus.;Andrea M Collins.;Thomas Darton.;Katherine Emary.;Saul N Faust.;Amy Flaxman.;Noshi Maria.;Christopher A Green.;Claudia Juarez Molina.;Ravindra Paidisetti.;Rajeka Lazarus.;Grace C Macaulay.;Florence McLean.;V Krishna Mohan.;M Gangadhara Naidu.;Maheshi N Ramasamy.;D Yogeswara Rao.;Nisha Singh.;Sophie Vernon.;Young Chan Kim.;Myron M Levine.;Xinxue Liu.;Andrew J Pollard.; .
来源: N Engl J Med. 2025年393卷17期1704-1714页
Salmonella enterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A.
5. A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain.
作者: Jeffrey N Katz.;Jamie E Collins.;Leslie Bisson.;Morgan H Jones.;James J Irrgang.;Faith Selzer.;Clare E Safran-Norton.;Kurt P Spindler.;Heidi Y Yang.;Swastina Shrestha.;Kim L Bennell.;James K Sullivan.;Melissa A Kluczynski.;Kaetlyn Arant.;Maame Opare-Addo.;Jamie L Huizinga.;Zoe Zimmerman.;Derek Sople.;Peter Tonsoline.;Madhuri Kale.;William M Wind.;Antonia F Chen.;Michael Freitas.;Bryson Lesniak.;Kelly Jordan.;Elizabeth G Matzkin.;Courtney Dawson.;Lutul Farrow.;Volker Musahl.;John J Leddy.;Scott D Martin.;Elena Losina.
来源: N Engl J Med. 2025年393卷17期1694-1703页
Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not been established.
6. European Study of Prostate Cancer Screening - 23-Year Follow-up.
作者: Monique J Roobol.;Ivo I de Vos.;Marianne Månsson.;Rebecka A Godtman.;Kirsi M Talala.;Elly den Hond.;Vera Nelen.;Arnauld Villers.;Gregoire Poinas.;Maciej Kwiatkowski.;Stephen Wyler.;Franz Recker.;Donella Puliti.;Giuseppe Gorini.;Marco Zappa.;Alvaro Paez.;Marcos Lujan.;Chris H Bangma.;Teuvo Tammela.;Fritz H Schröder.;Sebastiaan Remmers.;Jonas Hugosson.;Anssi Auvinen.; .
来源: N Engl J Med. 2025年393卷17期1669-1680页
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.
7. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
作者: Xiuning Le.;Tae Min Kim.;Herbert H Loong.;Arsela Prelaj.;Boon Cher Goh.;Lin Li.;Yong Fang.;Shun Lu.;Xiaorong Dong.;Lin Wu.;Yuki Shinno.;Gennaro Daniele.;Tsung-Ying Yang.;Hye Ryun Kim.;Gerrina Ruiter.;Jun Zhao.;Silvia Novello.;Liyun Miao.;Pasi A Jänne.;Koichi Goto.;Dominik Rüttinger.;Tine Descamps.;Jan Christoph Brase.;Weichao Bao.;Rui Li.;Nicoletta Brega.;Paolo Grassi.;Nicolas Girard.;Daniel Shao-Weng Tan.; .
来源: N Engl J Med. 2025年393卷18期1819-1832页
HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.
8. Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality.
作者: Fadima Cheick Haidara.;Laura Adubra.;Mahamadou Abdou.;Dagmar Alber.;Ulla Ashorn.;Yin Bun Cheung.;Elaine Cloutman-Green.;Mamadou Diallo.;Camilla Ducker.;Yue-Mei Fan.;Gwydion Gruffudd.;Lotta Hallamaa.;Tiia Haapaniemi.;Rikhard Ihamuotila.;Jane Juma.;Nigel Klein.;Juho Luoma.;Owen Martell.;Akshaya Murugesan.;Collins Okello.;Oumar Samaké.;Cheick Amadou Tidiane Traore.;Taru Vehmasto.;Kaisa Ylikruuvi.;Samba Sow.;Per Ashorn.
来源: N Engl J Med. 2025年393卷15期1498-1508页
Mass administration of azithromycin to children 1 to 59 months of age has been shown to reduce mortality among infants and children in this age group in some areas of sub-Saharan Africa. The largest effects have appeared to be among infants younger than 12 months of age, within 3 months after treatment; this observation motivated the design of the current trial.
9. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
作者: Ronald F van Vollenhoven.;Li Wang.;Joan T Merrill.;Yi Liu.;Chunde Bao.;Fen Li.;Jiankang Hu.;Chenghui Huang.;Jianhong Zhao.;Cibo Huang.;Hanyou Mo.;Wei Wei.;Fu'ai Lu.;Jingyang Li.;Dongbao Zhao.;Wenxiang Wang.;Lin Li.;Qing Zuraw.;Xiaofei Wang.;Xuebin Wang.;Jianmin Fang.;Fengchun Zhang.; .
来源: N Engl J Med. 2025年393卷15期1475-1485页
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to standard therapy.
10. Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.
作者: Hua Tu.;He Huang.;Yanfang Li.;Xiaojun Chen.;Chunyan Wang.;Min Zheng.;Yanna Zhang.;Weidong Zhao.;Yanling Feng.;Ting Wan.;Yongwen Huang.;Aijun Yu.;Weiguo Lu.;Jing Xiao.;Weiwei Shan.;Ping Zhang.;Changkun Zhu.;Danbo Wang.;Hu Zhou.;Jibin Li.;Beihua Kong.;Weiwei Feng.;Xipeng Wang.;Rongzhen Luo.;Xin Huang.;Jundong Li.;Zejian Lin.;Shuzhong Yao.;Jihong Liu.; .
来源: N Engl J Med. 2025年393卷15期1463-1474页
Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer.
11. Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.
作者: Natalie E Dean.;Amy M Crisp.;Azael Che-Mendoza.;Oscar D Kirstein.;Gloria A Barrera-Fuentes.;James T Earnest.;Henry N Puerta-Guardo.;Matthew H Collins.;Norma Pavia-Ruz.;Guadalupe Ayora-Talavera.;Gabriela González-Olvera.;Anuar Medina-Barreiro.;Wilbert Bibiano-Marín.;Shirin Jabbarzadeh.;M Elizabeth Halloran.;Ira M Longini.;Audrey Lenhart.;Lance A Waller.;Fabian Correa-Morales.;Jorge Palacio-Vargas.;Hector Gomez-Dantes.;Pablo Manrique-Saide.;Gonzalo M Vazquez-Prokopec.
来源: N Engl J Med. 2025年393卷14期1387-1398页
Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of walls and under furniture.
12. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
作者: Vallerie V McLaughlin.;Marius M Hoeper.;David B Badesch.;H Ardeschir Ghofrani.;J Simon R Gibbs.;Mardi Gomberg-Maitland.;Ioana R Preston.;Rogerio Souza.;Aaron B Waxman.;Grzegorz Kopeć.;Gisela Meyer.;Karen M Olsson.;Wei Fu.;Yaru Shi.;Barry Miller.;Samuel S Kim.;Harald S Mackenzie.;Michela Brambatti.;Mahesh J Patel.;Joerg Koglin.;Alexandra G Cornell.;Marc Humbert.; .
来源: N Engl J Med. 2025年393卷16期1599-1611页
Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial hypertension within the first year after diagnosis are unclear.
13. Hypertonic Saline or Carbocisteine in Bronchiectasis.
作者: Judy M Bradley.;Brenda O'Neill.;Daniel F McAuley.;James D Chalmers.;Anthony De Soyza.;Adam T Hill.;Mary Carroll.;Michael R Loebinger.;Jamie Duckers.;Mike Clarke.;Rebecca H McLeese.;Kathryn Ferguson.;Andrew Jackson.;Christina Campbell.;Clíona McDowell.;Ashley Agus.;John Norrie.;Fiona Copeland.;Damian G Downey.;Rory Convery.;Martin Kelly.;William Flight.;Nick P Talbot.;John R Hurst.;John Steer.;Muhammad Anwar.;Mitra Shahidi.;Timothy Gatheral.;Mohamed Etumi.;Anita L Sullivan.;Andreea Alina Ionescu.;Veeresh Patil.;Milan Bhattacharya.;Steven Caskey.;Denise Cosgrove.;Conor Hagan.;Amelia Shoemark.;Terence McManus.;Gareth Davies.;J Stuart Elborn.; .
来源: N Engl J Med. 2025年393卷16期1565-1577页
Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness.
14. Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
作者: Julian D Gillmore.;Ed Gane.;Jörg Täubel.;Björn Pilebro.;Andoni Echaniz-Laguna.;Justin Kao.;William Litchy.;Safi Shahda.;Alexandra Haagensen.;Liron Walsh.;Derek Smith.;Jessica Kachadourian.;Jonathan H Ward.;David Lebwohl.;Peijuan Zhu.;Yuanxin Xu.;Adia Leung.;Alison Sonderfan.;David E Gutstein.;Garen Manvelian.;David Adams.
来源: N Engl J Med. 2025年393卷14期1375-1386页
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liver.
15. Permethrin-Treated Baby Wraps for the Prevention of Malaria.
作者: Ross M Boyce.;Bonnie E Shook-Sa.;Ronnie Ndizeye.;Emmanuel Baguma.;Dana Giandomenico.;Caitlin A Cassidy.;Solomon Eshun.;Mark J Siedner.;Sarah G Staedke.;Moses Ntaro.;Jonathan J Juliano.;Raquel Reyes.;Edgar M Mulogo.
来源: N Engl J Med. 2025年393卷14期1399-1408页
Malaria remains a major cause of childhood death in sub-Saharan Africa. We leveraged the traditional practice of mothers carrying children on their backs in cloth wraps to assess whether treating the wraps with an insect repellent might provide a layer of protection against malaria.
16. Clesrovimab for Prevention of RSV Disease in Healthy Infants.
作者: Heather J Zar.;Eric A F Simões.;Shabir A Madhi.;Octavio Ramilo.;Shelly D Senders.;Julie S Shepard.;Kamolwish Laoprasopwattana.;Jorge Piedrahita.;Jose M Novoa.;Sergio L Vargas.;Marc Dionne.;Teresa Jackowska.;Enmei Liu.;Yasunori Ishihara.;Kazushige Ikeda.;Ying Zhang.;Radha A Railkar.;Jeannine Lutkiewicz.;Kalpit A Vora.;Xiaowei Zang.;Brian M Maas.;Andrew W Lee.;Andrea Guerra.;Anushua Sinha.; .
来源: N Engl J Med. 2025年393卷13期1292-1303页
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in healthy infants are needed.
17. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.
作者: Anna Martling.;Ida Hed Myrberg.;Mef Nilbert.;Henrik Grönberg.;Fredrik Granath.;Martin Eklund.;Tom Öresland.;Lene H Iversen.;Carola Haapamäki.;Martin Janson.;Karin Westberg.;Josefin Segelman.;Urban Ersson.;Mattias Prytz.;Eva Angenete.;Rebecka Bergström.;Markus Mayrhofer.;Bengt Glimelius.;Johan Lindberg.; .
来源: N Engl J Med. 2025年393卷11期1051-1064页
Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis, particularly among patients with tumors harboring somatic PIK3CA mutations. However, data from randomized trials are lacking.
18. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
作者: Sean Wharton.;Louis J Aronne.;Adam Stefanski.;Nasreen F Alfaris.;Andreea Ciudin.;Koutaro Yokote.;Bruno Halpern.;Alpana P Shukla.;Chunmei Zhou.;Lisa Macpherson.;Sheryl E Allen.;Nadia N Ahmad.;Suzanne R Klise.; .
来源: N Engl J Med. 2025年393卷18期1796-1806页
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.
19. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
作者: Sean Wharton.;Ildiko Lingvay.;Pawel Bogdanski.;Ruben Duque do Vale.;Stephan Jacob.;Tobias Karlsson.;Chaithra Shaji.;Domenica Rubino.;W Timothy Garvey.; .
来源: N Engl J Med. 2025年393卷11期1077-1087页
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity.
20. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
作者: James Chih-Hsin Yang.;Shun Lu.;Hidetoshi Hayashi.;Enriqueta Felip.;Alexander I Spira.;Nicolas Girard.;Yu Jung Kim.;Se-Hoon Lee.;Yurii Ostapenko.;Pongwut Danchaivijitr.;Baogang Liu.;Adlinda Alip.;Ernesto Korbenfeld.;Josiane Mourão Dias.;Benjamin Besse.;Antonio Passaro.;Ki-Hyeong Lee.;Hailin Xiong.;Soon-Hin How.;Ying Cheng.;Gee-Chen Chang.;Hiroshige Yoshioka.;Michael Thomas.;Danny Nguyen.;Sai-Hong Ignatius Ou.;Sanjay Mukhedkar.;Kumar Prabhash.;Manolo D'Arcangelo.;Jorge Alatorre-Alexander.;Juan Carlos Vázquez Limón.;Sara Alves.;Daniil Stroyakovskiy.;Marina Peregudova.;Mehmet Ali Nahit Şendur.;Ozan Yazici.;Raffaele Califano.;Vanesa Gutiérrez Calderón.;Filippo de Marinis.;Sang-We Kim.;Shirish M Gadgeel.;Scott Owen.;John Xie.;Tao Sun.;Jaydeep Mehta.;Raja Venkatasubramanian.;Mariah Ennis.;Elizabeth Fennema.;Mahesh Daksh.;Amy Roshak.;Julie Man.;Roland E Knoblauch.;Joshua M Bauml.;Mahadi Baig.;Sujay Shah.;Seema Sethi.;Byoung Chul Cho.; .
来源: N Engl J Med. 2025年393卷17期1681-1693页
Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
|